Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06038318 · ClinicalTrials.gov registry record · NA
Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer
A NA study of Anxiety and Stress, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 325
- Enrollment target
- 2
- Study locations
NCT06038318: Recruiting NA study of Anxiety and Stress, sponsored by Dana-Farber Cancer Institute.
NCT06038318 is a NA study of Anxiety and Stress that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 325 participants, below the 439-participant average among 364 other Anxiety trials with a reported enrollment target (26% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06038318, a NA study of Anxiety and Stress, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 325 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to find the best way to help participants and families manage the stress of facing a serious illness and be better able to "bounce back" or be resilient after a difficult situation. Participants will take part in the "Promoting Resilience in Stress Management" PRISM program, which is designed to provide skills to change or improve the impact of stress in everyday life. The name of the intervention used in this research study is: -PRISM (a mobile app program comprised of 6 sessions of skills-based, manualized resilience education)
Primary Outcome
Assessed by the CDRISC-10, a 10-item measures consisting of a 5-point Likert scale with answers ranging from 0 (not true at all) to 4 (true nearly all the time) for a total of 40 points. Higher scores reflect greater resilience. Evaluation will be based on the scores of the video and text cohorts vs. the self-guided cohort.
Interventions
- BEHAVIORAL PRISM Program Video Coach
- BEHAVIORAL PRISM Program Text Coach
- BEHAVIORAL mPRISM Program App
Study Locations (2)
Massachusetts
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2027-05-01 |
| Phase | NA |
What NCT06038318 shows while recruiting
NCT06038318 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 364 other Anxiety trials with a reported enrollment target (26% lower).
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 3 interventions - of which PRISM Program Video Coach is the first listed.
NCT06038318 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06038318 about?
NCT06038318 is a clinical study titled "Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer". The goal of this study is to find the best way to help participants and families manage the stress of facing a serious illness and be better able to "bounce back" or be resilient after a difficult situation. Participants will take part in the "Promoting Resilience in Stress Management" PRISM program...
What is the current status of trial NCT06038318?
This trial is currently recruiting. It is a NA study. The enrollment target is 325 participants. The study started on 2023-10-16. Estimated completion is 2027-05-01.
What conditions does trial NCT06038318 study?
This clinical trial studies the following conditions: Anxiety, Stress.
What interventions are being tested in trial NCT06038318?
The interventions under investigation include: PRISM Program Video Coach (BEHAVIORAL), PRISM Program Text Coach (BEHAVIORAL), mPRISM Program App (BEHAVIORAL).
Who is sponsoring clinical trial NCT06038318?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06038318 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06038318's enrollment target sits among peer trials
325 51st of 364 higher than 314 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI